Abstract
Since the discovery of P-glycoprotein (P-gp) in brain microvessels composing the human blood-brain barrier (BBB), ATPbinding cassette (ABC) transporters have been recognized as bottlenecks in the development and delivery of neuropharmaceuticals. ABC transporters are expressed predominately at the plasma luminal membrane of brain capillary endothelial cells. These ABC transporters are responsible for the efflux of their substrates from the endothelial cells to the bloodstream against the concentration gradient and thus limit the entry of some drugs within the central nervous system (CNS). Advanced quantitative molecular biology tools allowed gene and protein quantification of the components of microvessels isolated from different species including human. Recently, positron emission tomography using radiolabelled probes that are substrates of ABC transporters allowed the determination of their functional activity at the human BBB. Here, we summarized new information regarding the relative expression, substrate recognition pattern for CNS drugs and functional activity of ABC transporters that are quantitatively expressed at the human BBB.
Keywords: ATP-binding cassette transporters, blood-brain barrier, blood-cerebrospinal fluid barrier, P-glycoprotein, breast cancer resistance protein, multidrug resistance protein.
Current Pharmaceutical Design
Title:Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Volume: 20 Issue: 10
Author(s): Catarina Chaves, Ramzi Shawahna, Aude Jacob, Jean-Michel Scherrmann and Xavier Declèves*
Affiliation:
- Neuropsychopharmacologie des addictions (CNRS UMR 8206), Université Paris Descartes, Faculté de Pharmacie, Paris,France
Keywords: ATP-binding cassette transporters, blood-brain barrier, blood-cerebrospinal fluid barrier, P-glycoprotein, breast cancer resistance protein, multidrug resistance protein.
Abstract: Since the discovery of P-glycoprotein (P-gp) in brain microvessels composing the human blood-brain barrier (BBB), ATPbinding cassette (ABC) transporters have been recognized as bottlenecks in the development and delivery of neuropharmaceuticals. ABC transporters are expressed predominately at the plasma luminal membrane of brain capillary endothelial cells. These ABC transporters are responsible for the efflux of their substrates from the endothelial cells to the bloodstream against the concentration gradient and thus limit the entry of some drugs within the central nervous system (CNS). Advanced quantitative molecular biology tools allowed gene and protein quantification of the components of microvessels isolated from different species including human. Recently, positron emission tomography using radiolabelled probes that are substrates of ABC transporters allowed the determination of their functional activity at the human BBB. Here, we summarized new information regarding the relative expression, substrate recognition pattern for CNS drugs and functional activity of ABC transporters that are quantitatively expressed at the human BBB.
Export Options
About this article
Cite this article as:
Chaves Catarina, Shawahna Ramzi, Jacob Aude, Scherrmann Jean-Michel and Declèves Xavier*, Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration, Current Pharmaceutical Design 2014; 20 (10) . https://dx.doi.org/10.2174/13816128113199990466
DOI https://dx.doi.org/10.2174/13816128113199990466 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Current Drug Targets Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Graphene Oxide: A Carrier for Pharmaceuticals and a Scaffold for Cell Interactions
Current Topics in Medicinal Chemistry Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology
Current Medicinal Chemistry - Anti-Cancer Agents Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Peptide Self-Assemblies for Drug Delivery
Current Topics in Medicinal Chemistry Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Brain Tumor Detection and Classification by Hybrid CNN-DWA Model Using MR Images
Current Medical Imaging Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Molecular Basis for the Neuroprotective Properties of FKBP-Binding Immunophilin Ligands
Current Medicinal Chemistry - Central Nervous System Agents Therapeutic Exploitation of Apoptosis and Autophagy for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued) Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies
Current Topics in Medicinal Chemistry